CPDC Marks Sixteen Years of Innovation and Success
Celebrating our Contribution to Advancing Nuclear Medicine for the World
HAMILTON, ON, March 19, 2024 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development and commercialization of radiopharmaceuticals, is proud to celebrate its 16th anniversary today. Since 2008, CPDC has been at the forefront of advancing nuclear medicine for patients in Canada and worldwide. On this occasion, the Company extends its sincere appreciation to our many supporters, including the Ontario Institute for Cancer Research and the Government of Canada for their founding and continued financial support.
CPDC proudly acknowledges the recent surge of international attention directed towards its spin-out companies, including Fusion Pharmaceuticals and ARTMS Inc. This significant interest is an affirmation of Canada’s preeminent position in advancing groundbreaking medical isotope technologies.
On this anniversary, CPDC is grateful for the vision of its founding CEO, John Valliant, now CEO of Fusion Pharmaceuticals and a member of the CPDC Board of Directors. CPDC also expresses gratitude for the guidance and support provided by valued Canadian investment partners Genesys Capital and FACIT Inc. Finally, Damian Lamb, Co-Founder and Managing Director of Genesys Capital, deserves special mention for his role as the inaugural Chair of the Board of Fusion Pharmaceuticals, helping to guide our spin-out company’s journey from its inception to its successful initial public offering.
« Our 16th anniversary is an occasion to reflect upon our achievements and to thank all who have supported CPDC over the years, including our past and present Board members, along with industry, academic and government partners, and our partners in the global nuclear medicine community,” said Owen Roberts, CEO of CPDC. “As we look ahead, we remain committed to investing and supporting the development and commercialization of radiopharmaceuticals, and are excited by our pipeline of current projects and opportunities.”
CPDC proudly acknowledges the recent surge of international attention directed towards its spin-out companies, including Fusion Pharmaceuticals and ARTMS Inc. This significant interest is an affirmation of Canada’s preeminent position in advancing groundbreaking medical isotope technologies.
On this anniversary, CPDC is grateful for the vision of its founding CEO, John Valliant, now CEO of Fusion Pharmaceuticals and a member of the CPDC Board of Directors. CPDC also expresses gratitude for the guidance and support provided by valued Canadian investment partners Genesys Capital and FACIT Inc. Finally, Damian Lamb, Co-Founder and Managing Director of Genesys Capital, deserves special mention for his role as the inaugural Chair of the Board of Fusion Pharmaceuticals, helping to guide our spin-out company’s journey from its inception to its successful initial public offering.
« Our 16th anniversary is an occasion to reflect upon our achievements and to thank all who have supported CPDC over the years, including our past and present Board members, along with industry, academic and government partners, and our partners in the global nuclear medicine community,” said Owen Roberts, CEO of CPDC. “As we look ahead, we remain committed to investing and supporting the development and commercialization of radiopharmaceuticals, and are excited by our pipeline of current projects and opportunities.”
About CPDC
CPDC is a not-for-profit corporation founded in 2008 to advance probe (chemical agents that will carry medical isotopes to targets in the body) discovery, development, and clinical research, and provide a reliable supply of radiopharmaceuticals. CPDC’s mission is to improve the quality of Canadian patients’ lives through the commercialization of advanced research and the clinical development of nuclear medicine. In the past 15 years, CPDC has created four Canadian commercial entities that have advanced the availability of radiopharmaceuticals to the Canadian medical community. CPDC’s self-funding business model will continue to identify and advance critical radiopharmaceuticals to meet the needs of Canadian patients and physicians through collaboration with partners including industry, academia, and government. For more information on CPDC, visit www.cpdc.ca and follow on LinkedIn.
Contact:
Owen Roberts, CEO, CPDC: owen@cpdc.ca
Contact:
Owen Roberts, CEO, CPDC: owen@cpdc.ca
